Scientists Re-Examine old data to see which patients benefit from extra antibiotic for staph blood infection
NCT ID NCT07155590
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at data from two previous clinical trials involving 369 patients with Staphylococcus aureus bloodstream infections. Researchers want to see if adding the antibiotic fosfomycin to standard care helps certain patient groups more than others. They will classify patients by infection type and risk level to find who might benefit most. The goal is to improve treatment decisions for this serious infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fosfomycin
- What this could lead to
- If successful, this could help doctors identify which patients with staph bloodstream infections are most likely to benefit from adding fosfomycin to standard treatment.
- What could go wrong
- This is a post-hoc analysis, not a new trial, so results are less reliable. The original trials did not show consistent benefit, and the analysis may not have enough power to confirm findings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCAL AUREUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Catalonia, 08907, Spain
-
Hospital Universitario Virgen de Macarena
Seville, 41009, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.